Shopping Cart 0
Cart Subtotal
USD 0

Novaliq GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops dermatological products, novel ophthalmic, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears a preservative free eye drop product for the relief of discomfort under dry eye syndrome. Novaliq also produces pipeline products for the treatment of glaucoma and other retinal diseases. The company offers its SFA technology as a delivery platform for external co-development cooperations. It licenses its SFA technology to distribution partners who completes registration studies. Novaliq is headquartered in Heidelberg, Germany.

Novaliq GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Novaliq GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Novaliq GmbH, Medical Devices Deals, 2012 to YTD 2018 9

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novaliq GmbH, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Novaliq Raises USD53 Million in Venture Financing 11

Novaliq Raises USD 18 Million In Venture Financing 12

Novaliq Raises USD 5.2 Million In Venture Financing 13

Partnerships 14

Novaliq Enters into Partnership with University of Cologne 14

Licensing Agreements 15

AFT Pharma Enters into Licensing Agreement with Novaliq 15

URSAPHARM Enters into Licensing Agreement with Novaliq 16

Novaliq GmbH-Key Competitors 17

Novaliq GmbH-Key Employees 18

Novaliq GmbH-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Corporate Communications 20

Jun 27, 2017: NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer 20

Product News 21

10/02/2017: German Ophthalmological Society (DOG) Honors Uta Gehlsen, PhD, with Prestigious Scientific Award for Her Research on the Use of Semifluorinated Alkanes in Dry Eye Treatment 21

Clinical Trials 22

Nov 09, 2017: Novaliq announces first patient randomized in its ESSENCE phase 2b/3 trial of CyclASol for the treatment of the signs and symptoms of dry eye disease 22

Jan 05, 2017: Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol in Adults with Moderate to Severe Dry Eye Disease 23

Appendix 24

Methodology 24

About GlobalData 24

Contact Us 24

Disclaimer 24


List Of Figure

List of Figures

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Novaliq GmbH, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Novaliq GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Novaliq GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Novaliq GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Novaliq GmbH, Medical Devices Deals, 2012 to YTD 2018 9

Novaliq GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novaliq Raises USD53 Million in Venture Financing 11

Novaliq Raises USD 18 Million In Venture Financing 12

Novaliq Raises USD 5.2 Million In Venture Financing 13

Novaliq Enters into Partnership with University of Cologne 14

AFT Pharma Enters into Licensing Agreement with Novaliq 15

URSAPHARM Enters into Licensing Agreement with Novaliq 16

Novaliq GmbH, Key Competitors 17

Novaliq GmbH, Key Employees 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Novaliq GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.